Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

CARE-MS | Investigators, Raymond Hupperts

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1829-1839
JournalLancet
Volume380
Issue number9856
DOIs
Publication statusPublished - 24 Nov 2012

Cite this